Q-omics provides the consensus-scored GOT2P6 profile across patient tissues and cancer cell-line models. GOT2P6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GOT2P6 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, GOT2P6 RNA expression shows 7,025 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LIHC, KICH, and LAML as cancer lineages where GOT2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOT2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOT2P6 survival associations across molecular data types. GOT2P6 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOT2P6 RNA expression–survival associations across cancer types. High GOT2P6 expression shows unfavorable associations in LIHC, DLBC, BLCA, STAD and GBM, but favorable associations in LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GOT2P6 RNA expression.
This table summarizes GOT2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GOT2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOT2P6 shows lower tumor expression in KICH and READ and higher tumor expression in STAD, COAD, LUSC and CHOL. The KICH box plot shows higher GOT2P6 RNA expression in normal versus tumor tissue (log2 FC = −0.036, t-test p < 0.001).
This table shows molecular features associated with GOT2P6 in patient tissues and cancer cell lines. In patient samples, GOT2P6 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
